BNGO - Bionano Genomics, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
San Diego,
United States
Type: Equity
BNGO price evolution
BNGO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $21.43 | $16.16 | $18.35 | |
| Short term investments | $8.52 | $37.01 | $83.94 | |
| Net receivables | $5.32 | $6.25 | $8.31 | $9.32 |
| Inventory | $14.32 | $19.48 | $19.59 | $22.89 |
| Total current assets | $46.98 | $60.57 | $85.61 | $140.12 |
| Long term investments | $0.4 | |||
| Property, plant & equipment | $26.18 | $32.49 | $33.6 | $32.48 |
| Goodwill & intangible assets | $30.02 | $31.73 | $33.97 | |
| Total noncurrent assets | $68.8 | $72.38 | $74.29 | |
| Total investments | $8.92 | $37.01 | $83.94 | |
| Total assets | $87.36 | $129.36 | $158 | $214.4 |
| Current liabilities | ||||
| Accounts payable | $8.7 | $8.73 | $9.84 | $10.38 |
| Deferred revenue | $1.42 | $1.17 | $0.94 | |
| Short long term debt | $21.76 | $31.54 | $72.24 | |
| Total current liabilities | $32.95 | $37.17 | $58.51 | $100.03 |
| Long term debt | $3.55 | $5.81 | $6.33 | $7.17 |
| Total noncurrent liabilities | $11.85 | $16.72 | $18.22 | |
| Total debt | $27.57 | $37.87 | $79.41 | |
| Total liabilities | $38.49 | $49.03 | $75.22 | $118.25 |
| Shareholders' equity | ||||
| Retained earnings | -$673.1 | -$628.85 | -$612.63 | -$581.21 |
| Other shareholder equity | $1.53 | -$0 | -$0.02 | $0.02 |
| Total shareholder equity | $80.34 | $82.77 | $96.16 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $18.35 | $5.49 | $24.57 | $38.45 |
| Short term investments | $83.94 | $108.09 | $226.04 | |
| Net receivables | $9.32 | $7.5 | $4.93 | $2.78 |
| Inventory | $22.89 | $29.76 | $12.39 | $3.32 |
| Total current assets | $140.12 | $157.3 | $272.41 | $46.79 |
| Long term investments | ||||
| Property, plant & equipment | $32.48 | $28.96 | $20.93 | $4.91 |
| Goodwill & intangible assets | $33.97 | $118.43 | $83 | $8.65 |
| Total noncurrent assets | $74.29 | $150.2 | $104.69 | $13.66 |
| Total investments | $83.94 | $108.09 | $226.04 | |
| Total assets | $214.4 | $307.5 | $377.1 | $60.45 |
| Current liabilities | ||||
| Accounts payable | $10.38 | $12.53 | $9.7 | $2.93 |
| Deferred revenue | $0.94 | $0.87 | $0.68 | $0.42 |
| Short long term debt | $72.24 | $2.54 | $1.77 | |
| Total current liabilities | $100.03 | $35.88 | $21.84 | $8.94 |
| Long term debt | $7.17 | $3.62 | $8.93 | $16.33 |
| Total noncurrent liabilities | $18.22 | $22.22 | $18.14 | $16.42 |
| Total debt | $79.41 | $11.67 | $10.7 | $16.33 |
| Total liabilities | $118.25 | $58.1 | $39.98 | $25.37 |
| Shareholders' equity | ||||
| Retained earnings | -$581.21 | -$348.71 | -$216.12 | -$143.68 |
| Other shareholder equity | $0.02 | -$1.12 | -$0.54 | $0 |
| Total shareholder equity | $96.16 | $249.4 | $337.12 | $35.08 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.07 | $7.77 | $8.77 | $10.72 |
| Cost of revenue | $5.19 | $5.95 | $8.28 | |
| Gross Profit | -$8.45 | $2.58 | $2.82 | $2.44 |
| Operating activities | ||||
| Research & development | $6.83 | $9.78 | $11.7 | |
| Selling, general & administrative | $11.56 | $19.54 | $15.69 | |
| Total operating expenses | $14.18 | $19.6 | $33.95 | $23.94 |
| Operating income | -$17.02 | -$31.12 | -$21.5 | |
| Income from continuing operations | ||||
| EBIT | -$16.2 | -$31.32 | -$39.03 | |
| Income tax expense | $0.02 | $0.03 | -$0.02 | -$0.04 |
| Interest expense | $0.38 | $0.12 | $4.9 | |
| Net income | ||||
| Net income | -$44.25 | -$16.22 | -$31.42 | -$43.89 |
| Income (for common shares) | -$16.22 | -$31.42 | -$43.89 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.12 | $27.8 | $17.98 | $8.5 |
| Cost of revenue | $26.55 | $21.86 | $14.11 | $5.73 |
| Gross Profit | $9.57 | $5.95 | $3.87 | $2.77 |
| Operating activities | ||||
| Research & development | $54.03 | $49.05 | $22.48 | $10.26 |
| Selling, general & administrative | $93.5 | $88.6 | $58.49 | $31.07 |
| Total operating expenses | $221.36 | $137.87 | $81.03 | $41.33 |
| Operating income | -$211.8 | -$131.92 | -$77.16 | -$38.56 |
| Income from continuing operations | ||||
| EBIT | -$227.31 | -$130.41 | -$77.22 | -$38.56 |
| Income tax expense | $0.06 | $1.88 | -$5.72 | $0.03 |
| Interest expense | $5.12 | $0.3 | $0.93 | $2.52 |
| Net income | ||||
| Net income | -$232.49 | -$132.6 | -$72.44 | -$41.11 |
| Income (for common shares) | -$232.49 | -$132.6 | -$72.44 | -$41.11 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$16.22 | -$31.42 | -$43.89 | |
| Operating activities | ||||
| Depreciation | $3.13 | $3.08 | $3.67 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.58 | $3.02 | $3.37 | |
| Total cash flows from operations | -$20.98 | -$28.13 | -$29.78 | |
| Investing activities | ||||
| Capital expenditures | -$0.08 | -$0.03 | -$0.74 | |
| Investments | $28.71 | $47.61 | -$54.63 | |
| Total cash flows from investing | $70.84 | $28.63 | $47.59 | -$55.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $11.19 | $15.06 | $11.02 | |
| Net borrowings | -$11.73 | -$36.68 | $66.47 | |
| Total cash flows from financing | -$17.57 | -$1.98 | -$21.62 | $68.48 |
| Effect of exchange rate | -$0 | -$0 | -$0.03 | $0.05 |
| Change in cash and equivalents | -$9.15 | $5.67 | -$2.19 | -$16.62 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$232.49 | -$132.6 | -$72.44 | -$41.11 |
| Operating activities | ||||
| Depreciation | $13.97 | $10.1 | $4.04 | $1.48 |
| Business acquisitions & disposals | $0.1 | -$30.65 | -$49.09 | -$2.45 |
| Stock-based compensation | $15.18 | $22.42 | $9.72 | $1.55 |
| Total cash flows from operations | -$125.18 | -$124.82 | -$71.93 | -$38.31 |
| Investing activities | ||||
| Capital expenditures | -$1.69 | -$3.17 | -$2.07 | |
| Investments | $25.75 | $116.69 | -$226.91 | |
| Total cash flows from investing | $24.16 | $82.77 | -$278.06 | -$2.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $56.38 | $23.04 | $351.12 | $66.63 |
| Net borrowings | $66.43 | -$0.04 | -$15.01 | -$4.72 |
| Total cash flows from financing | $113.81 | $23.01 | $336.11 | $61.9 |
| Effect of exchange rate | $0.07 | -$0.04 | ||
| Change in cash and equivalents | $12.86 | -$19.08 | -$13.88 | $21.14 |
News
Fundamentals
| Market cap | $474.19M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 88.47M |
| Revenue | $33.33M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$135.78M |
| Revenue Q/Q | -34.83% |
| Revenue Y/Y | -0.82% |
| P/E ratio | -3.49 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 14.23 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.53 |
|---|---|
| ROA | -92.19% |
| ROE | N/A |
| Debt/Equity | 1.23 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.43 |
| Quick ratio | 0.99 |